[News Space=Reporter seungwon lee] Hugel, a global total medical aesthetics company, has solidified its position as a leading player in K-aesthetics in the US, the world's largest botulinum toxin market. Starting this year, just two years after its launch, the company plans to adopt a hybrid sales model combining direct sales and partnerships to successfully establish its US business and build upon this foundation to become a leading global medical aesthetics company.

Hugel participated in the Asia-Pacific (APAC) track presentation at the JP Morgan Healthcare Conference in San Francisco on the 15th (local time). The JP Morgan Healthcare Conference, the world's largest healthcare investment symposium, is a forum where global pharmaceutical and biotech companies share industry trends and management strategies.

“We expect to achieve annual sales of 900 billion won by 2028 as we expand hybrid sales and strategic investments in the U.S. market,” said Carrie Strom, CEO of Hugel Global. “In particular, we aim to generate more than 30% of our total sales in the U.S. market.”

After receiving FDA approval in 2024, Hugel began full-scale US sales in 2025 with local distribution partner Benev. This year, the company will embark on a "hybrid sales" strategy, combining distribution through existing partners with direct sales. This strategy aims to significantly increase profitability, driving stable sales and market share expansion.

Ultimately, the company plans to achieve a 10% market share in the US by 2028 and 14% by 2030. Furthermore, the company aims to achieve annual sales of KRW 900 billion by 2028, representing a compound annual growth rate (CAGR) of 25%. The company aims to maintain an EBITDA margin of 50% while simultaneously achieving sales growth.

Hugel will also focus on expanding its product portfolio to create synergies with its existing flagship products, including toxins and HA fillers. In particular, the company plans to pursue strategic business development initiatives such as technology licensing and product co-promotion, addressing market demand centered on skin boosters and building an aesthetic lineup optimized for the global market.

Carrie Strom, CEO of Hugel Global, emphasized, “We will pursue a full-scale global transformation by expanding our global market share, focusing on the U.S., and aggressively expand sales through business performance such as portfolio restructuring.” She added, “Above all, we plan to make company-wide efforts to maintain a sound financial structure, including maintaining the industry’s highest operating profit margin.”